Localization of Parathyroid Adenoma by Fluorocholine PET/MRI (Positron Emission Tomography -MRI)

Assuta Medical Center50 enrolled

Overview

A comparative prospective study to evaluate different imaging modalities (pet-ct and pet-mr) prior to surgery in parathyroid tumor patients.

Patients with Hyperthyroidism and surgery indication will be recruited and directed to imagine exams. in addition to the conservative 99mTc-MIBI (methoxyisobutylisonitrile) and US, patients will also undergo 18FCH (¹⁸F-choline) PET/MRI for detecting adenomas and their location. imaging experts will decode the imaging exams. sensitivity and specificity of the exams will be examined.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

DIAGNOSTIC

Masking

NONE

Enrollment

Conditions

Primary Hyperthyroidism

Interventions

PET-MRDEVICE

Patients with Hyperthyroidism and surgery indication will be recruited and directed to imagine exams. In addition to the conservative 99mTc-MIBI and US, patients will also undergo 18FCH PET/MRI for detecting adenomas and their location.

PET-CTDEVICE

Eligibility

Sex: ALLMin age: 18 YearsMax age: 50 Years

Medical Language ↔ Plain English

Inclusion Criteria: Patients who meet the criteria accepted in the World Health Organization (WHO) analysis: * Symptomatic patients (constipation, depression, peptic ulcer, pathologic fractures, chronic fatigue, pain from a urinary tract stones etc..) or at least one of the following criteria: * Blood calcium levels above 1 more than normal * Creatinine clearance decreased in 30% from age expected * Urine Creatinine above 400 mg in 24 hours Exclusion Criteria: * Patients with hyperthyroidism secondary and tertiary (secondary to kidney disease) * Patients who are not eligible to sign an informed consent * Pregnant women * Patients with sensitivity (allergy) technetium or 18FCH

Locations (1)

Assuta Medical Center

Tel Aviv, Israel, Israel

Outcomes

Primary Outcomes

Adenomas size and location

Location of adenomas by a report analyzing the pathological examination (PET-CT/PET-MR output).

Time frame: 24 months

Secondary Outcomes

Parathyroid hormone levels

approval late addition level of parathyroid hormone (PTH) before and during the course of the operation after the conclusion of adenomas (Hormone levels).

Time frame: 24 months

Chronic disease duration

time from chronic diseases indication and duration of symptoms measured in months (from the medical records).

Time frame: 24 months

Disease related medication consumption

Disease related medication consumption measured in miligram (mg) for each medication (from medical records).

Time frame: 24 months

Central Contacts

Avi Hefetz, MD

CONTACT

972528661361 avihef1@gmail.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.